bluuebunny/crossref_metadata_2025_split huggingface dataset:
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia
Authors: Lazo Guillermo , Kantarjian Hagop , Estey Elihu , Thomas Deborah , O'Brien Susan , Cortes Jorge 
Published: April 2003

AbstractBACKGROUNDApproximately 20–30% of patients with acute promyelocytic leukemia (APL) who are treated with all‐trans retinoic acid (ATRA) and an anthracycline develop recurrent disease. It has been reported that arsenic trioxide (As2O3) is effective in this setting. The authors report the experience of The M. D. Anderson Cancer Center with As2O3 in the treatment of patients with recurrent APL.METHODSTwelve patients who developed recurrent APL after treatment with ATRA were included. Patients received intravenous As2O3 0.15 mg/kg per day until they achieved a complete remission (CR) or up to a maximum of 60 days. Their median age was 44 years (range, 26–72 years), and the median duration of first remission was 52 weeks (range, 23–292 weeks).RESULTSAll 12 patients achieved a CR. The median time to achieve CR was 52 days (range, 27–75 days). Seven of 10 evaluable patients achieved a molecular remission (i.e., polymerase chain reaction [PCR] analysis was negative for the gene encoding fusion of the nuclear receptor for retinoic acid to the PML gene at the time of CR; 70% of patients; 95% confidence interval, 0.35–0.93), and all other patients had negative PCR results after they received postremission therapy. All patients received subsequent therapy: Four patients received As2O3 alone, six patients received As2O3 with other chemotherapeutic agents, and two patients received idarubicin plus ATRA without As2O3. Eight patients continued in CR after a median follow‐up of 24 months (range, 9–45 months). Side effects were mild, except for two patients who developed Grade 2 and 3 peripheral neuropathy, respectively; one of those patients required discontinuation of therapy.CONCLUSIONSAs2O3 is effective and well tolerated therapy for patients with recurrent APL. Molecular remission may be achieved at the time of CR in the majority of patients, and remissions are durable. Cancer 2003;97:2218–24. © 2003 American Cancer Society.DOI 10.1002/cncr.11314
Extranodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue of the head and neck area
Authors: Wenzel Catharina , Fiebiger Wolfgang , Dieckmann Karin , Formanek Michael , Chott Andreas , Raderer Markus 
Published: April 2003

AbstractBACKGROUNDMucosa‐associated lymphoid tissue (MALT) lymphoma is a distinct entity with specific clinical and pathologic features that may affect diverse organs. MALT–lymphomas remain localized within their original environment for a long period of time. As recent data have demonstrated a relatively high rate of multiorgan involvement at diagnosis, the authors have retrospectively evaluated 36 patients presenting with MALT‐lymphoma in the head and neck area. The authors focused on patients' disease localization, initial treatment, clinical course, and follow‐up.METHODSThirty‐six patients with a histologically verified diagnosis of an extranodal marginal zone B‐cell MALT‐lymphoma arising in the head and neck area were included in this retrospective analysis.RESULTSTreatment consisted of surgical resection as the sole treatment in 4 patients (11%), surgical resection with consecutive radiotherapy in 13 patients (36%), radiotherapy alone in 11 patients (31%), chemotherapy in 2 patients (6%), surgical resection plus radiotherapy and chemotherapy in 4 patients (11%), and combined radiation and chemotherapy in 1 patient (3%). Complete and partial disease remissions after initial treatment were achieved in 22 (61%) and 13 patients (36%), respectively, whereas one patient refused any therapy. Four patients (11%) were lost to follow‐up and 15 patients (43%) have had disease recurrence after a median time of 11 months (range, 3–80 months).CONCLUSIONSThese data suggest that MALT‐lymphomas of the head and neck area are preferentially treated using local modalities such as radiation and/or resection. This practice, however, is associated with an unexpectedly high rate of dissemination or disease recurrence. Obtaining an initial complete response is crucial in these patients. According to previous data, the possibility of understaging in such patients cannot be ruled out. Clinical trials with application of systemic treatment are warranted for these patients. Cancer 2003;97:2236–41. © 2003 American Cancer Society.DOI 10.1002/cncr.11317
Effect of stereotactic core needle biopsy on pathologic measurement of tumor size of T1 invasive breast carcinomas presenting as mammographic masses
Authors: Charles Melita , Edge Stephen B. , Winston Janet S. , Hurd Thelma C. , Driscoll Deborah L. , Stomper Paul C. 
Published: April 2003

AbstractBACKGROUNDStereotactic core needle biopsy (SCNB) may change the size of the tumor defined pathologically at excision. This may alter tumor stage and affect recommendations for adjuvant systemic therapy. This study evaluated the effect of SCNB on assessment of pathologic tumor size and staging for invasive breast carcinomas presenting as mammographic masses.METHODSThe authors reviewed the mammographic and pathologic size of 138 mammographically detected invasive carcinomas manifested as a measurable mass lesion on mammography and as a 20 mm or smaller lesion on pathologic evaluation. Group A included 61 patients with SCNB before surgical excision and the Group B (the control group) included 77 patients who had surgical excision without SCNB. The size of the mammographic central mass was compared with the pathologic tumor size. The difference between the mammographic and pathologic size was determined and the findings in Group A and B were compared by the Mann–Whitney U test.RESULTSThe mean mammographic size was 12.2 and 11.83 mm and the mean pathologic size was 9.85 and 9.87 mm for Groups A and B, respectively. The mean difference between mammographic and pathologic size in Groups A and B was 2.3 mm and 1.96 mm, respectively (P = not significant).CONCLUSIONSFor soft tissue masses, the difference between mammographic size and pathologic size of invasive carcinoma at excision does not appear to be affected by the use of SCNB. Except in the circumstance of complete removal of the cancer by SCNB, the pathologic size and stage of the excised tumor after SCNB is not altered significantly by SCNB. Cancer 2003;97:2137–41. © 2003 American Cancer Society.DOI 10.1002/cncr.11336
Adenosquamous histology predicts a poor outcome for patients with advanced‐stage, but not early‐stage, cervical carcinoma
Authors: Farley John H. , Hickey Kimberly W. , Carlson Jay W. , Rose G. Scott , Kost Edward R. , Harrison Terry A. 
Published: April 2003

AbstractBACKGROUNDThe objective of this study was to compare survival between patients with adenocarcinoma and patients with adenosquamous carcinoma of the cervix.METHODSPatients who were diagnosed with invasive cervical carcinoma from 1988 to 1999 were identified from the Automated Central Tumor Registry for the United States Military Health Care System. Clinical data, including race, age at diagnosis, histology, tumor grade, disease stage, lymph node status, treatment modality, and survival, were collected. Survival analysis was performed with Kaplan–Meier survival curves and compared using the log‐rank test.RESULTSA total of 273 women were identified, 185 women with a histologic diagnosis of adenocarcinoma (AC) and 88 women with a diagnosis of adenosquamous carcinoma (ASC). Among the women with ASC, only 5% had Grade 1 tumors, and 66% had Grade 3 tumors. By comparison, among the women with AC, 37% had Grade 1 tumors, and 26% had Grade 3 tumors (P < 0.001). There was no difference in the incidence of positive lymph nodes or in the number of patients who underwent radical hysterectomy as primary treatment between patients with ASC and patients with AC. More patients with ASC received radiation therapy (51% vs. 28%) or chemotherapy (29% vs. 12%) as treatment (P < 0.001). Patients who had tumors with ASC histology had a significantly decreased 5‐year survival rate compared with patients who had tumors with AC histology (65% vs. 83%; P < 0.002). When patients with early‐stage cervical carcinoma (International Federation of Gynecology and Obstetrics [FIGO] Stage I) were examined separately, there was no statistically significant difference in the 5‐year survival rate (AC, 89%; ASC, 86%; P = 0.644). However, when patients with advanced‐stage disease (FIGO Stages II–IV) were analyzed, ASC was associated with a significant decrease in median and overall survival (P = 0.01). When the results were analyzed by grade, patients who had tumors with ASC histology had a shorter survival compared with patients who had AC histology of any grade; however, this was a significant difference only for patients with Grade 1 tumors: The 5‐year survival rate for patients with Grade 1 AC was 93%, compared with 50% for patients with Grade 1 ASC (P < 0.01).CONCLUSIONSASC histology appears to be an independent predictor of poor outcome in women with cervical carcinoma compared with their counterparts who have pure AC. The significant decrease in survival was observed only in patients with advanced‐stage cervical carcinoma. This decreased survival may be related mainly to the grade of ASC. Cancer 2003;97:2196–202. Published 2003 American Cancer Society.DOI 10.1002/cncr.11371
Hypersensitivity and idiosyncratic reactions to oxaliplatin
Authors: Thomas Rebecca R. , Quinn Mary G. , Schuler Barbara , Grem Jean L. 
Published: April 2003

AbstractBACKGROUNDOxaliplatin is a third‐generation platinum analog that is used to treat a variety of solid tumors, particularly colorectal carcinoma. Patients may develop hypersensitivity reactions, although this complication occurs infrequently.METHODSThree patients developed hypersensitivity reactions to oxaliplatin while undergoing treatment on a Phase I trial of oxaliplatin and capecitabine. An Entrez PUBMED search was performed to identify other cases.RESULTSTwo patients experienced the abrupt onset of erythema alone or with pruritis during the 9th and 11th infusions of oxaliplatin, whereas the other patient developed fever and mild dyspnea a few hours after the 9th oxaliplatin infusion. All 3 patients were rechallenged successfully for at least 1 additional oxaliplatin infusion by using oral dexamethasone, 20 mg orally, 6 and 12 hours before the administration of oxaliplatin and by administering intravenously 125 mg of solumedrol, 50 mg of diphenhydramine, and 50 mg of cimetidine 30 minutes before oxaliplatin. The literature review suggests two distinct patterns of reactions: classic hypersensitivity (as experienced by the first two patients) and idiosyncratic reactions (as experienced by the third patient).CONCLUSIONSPatients who develop mild to moderate hypersensitivity to oxaliplatin may be pretreated with steroids and antagonists of Type 1 and 2 histamine receptors, whereas patients who develop severe reactions are unlikely to tolerate further therapy. Cancer 2003;97:2301–7. Published 2003 American Cancer Society.DOI 10.1002/cncr.11379
New method to measure control performance of dust palliatives on unpaved roads at federal facilities
Authors: Muleski Gregory E. , Trenholm Andrew R. , Gebhart Dick L. , Franke Deborah L. , Cowherd Chatten 
Published: April 2003

AbstractMilitary training activities often produce significant dust emissions from unpaved travel surfaces. Because
failure to comply with environmental regulations could adversely affect training operations, prudent use of
chemical palliatives for control of dust from unpaved surfaces enhances the Army's land‐based training
capability, mission, and combat readiness.This article describes a new, more efficient method to determine the control effectiveness of palliatives on
roads at Army facilities. Rather than attempting to quantify “absolute” emission rates, the
“mobile sampler” described in this article relies on relative measures. As compared to the methods
used in previous field studies, the mobile sampler is not only more efficient in terms of time and labor required,
it also provides greater reproducibility and relieves many of the restrictions placed on acceptable test sites
when using test methods for absolute emission levels. © 2003 Wiley Periodicals, Inc.
Individual job‐choice decisions and the impact of job attributes and recruitment practices: A longitudinal field study
Authors: Boswell Wendy R. , Roehling Mark V. , LePine Marcie A. , Moynihan Lisa M. 
Published: April 2003

AbstractThe present research is intended to contribute to the understanding of how job‐choice decisions are
made and the role of effective and ineffective recruiting practices in that
process. The issues are examined by tracking job seekers through the job search and choice process. At multiple
points in the process, structured interviews are used to elicit information from the job seekers pertaining to
how they are making their decision and what factors play a role. Results provide theoretical and practical
insights into the organizational and job attributes important to job choice, as well as how specific recruiting
practices may exert a significant influence, positive or negative, on job‐choice decisions. For example,
our findings reinforced the importance of providing job seekers the opportunity to meet with multiple (and
high‐level) organizational constituents, impressive site‐visit arrangements, and frequent and
prompt follow‐up. Also, imposing a deadline (i.e., “exploding offer”) showed little
effect on job‐choice decisions. Recommendations for recruitment practice and continued research are
provided. © 2003 Wiley Periodicals, Inc.
Time and space: Reframing the training and development agenda
Authors: Baird Lloyd , Griffin Darrell , Henderson John 
Published: April 2003

AbstractIn this article, we review how time and space relationships are reframing the training and development agenda.
As the speed of business moves faster and boundaries become less relevant, we need ways of expanding and choosing
how and when learning and development can take place. We need ways to target development on specific business
issues and deliver improved performance in less time with reduced cost. We define a learning options framework to
help organize, integrate, synthesize, and better fit training and development methodologies to business realities.
Specific knowledge, tools, and examples are provided to show how organizations are identifying and choosing among
development options. © 2003 Wiley Periodicals, Inc.
Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka
Authors: Penzel Roland , Hoegel Josef , Schmitz Waltraud , Blaeker Hendrik , Morresi‐Hauf Alicia , Aulmann Sebastian , Hecker Erich , Mechtersheimer Gunhild , Otto Herwart F. , Rieker Ralf J. 
Published: April 2003

AbstractUsing comparative genomic hybridisation, we investigated chromosomal imbalances in 28 cases of thymic epithelial neoplasms including type A, B2, B3, the A component of type AB and different subtypes of type C thymoma. To identify different patterns of chromosomal aberrations associated with the biological behaviour and the histological diversity of thymomas, a hierarchical cluster analysis of 65 cases was performed. The here‐reported Comparative Genomic Hybridisation (CGH) data (28 cases) of partly uninvestigated tumour subtypes were pooled with previously published data of chromosomal imbalances of 37 thymomas (Zettl et al. [Am J Pathol 2000;157:257–66]). The analysis of 278 chromosomal subbands yielded 2 main clusters. The first main cluster was characterised by gains of the chromosomal arm 1q, consisted only of type C and B3 thymomas and was further subdivided into 2 subgroups. To the first subgroup only thymomas were attributed, which, in addition to gains of the chromosomal arm 1q, showed losses on 6q and 16q, whereas tumours belonging to the second subgroup exhibited no further recurrent chromosomal alterations. The second main cluster was formed by a heterogeneous group of thymoma types (types A, AB, B2, B3 and C), showing no specific pattern of chromosomal imbalances. In 19 thymomas, no chromosomal imbalances could be detected (3 type B2 and 5 type A thymomas of our study as well as 11 type A thymomas investigated by Zettl et al., Am J Pathol 2000;157:257–66). Chromosomal imbalances were more frequent in type C thymomas than in other subtypes. The distribution of tumour stages according to Masaoka (p = 0.003) and the World Health Organisation (WHO) classification (p < 0.0001) was significantly different in the clusters and subgroups obtained. The groups reflect the staging system and the WHO classification and show that type B3 and type C carcinomas have a strong relationship concerning their chromosomal imbalances. Furthermore, chromosomal imbalances detected in some type A thymomas might be responsible for the aggressive behaviour described in a few cases of this thymoma subtype. © 2003 Wiley‐Liss, Inc.
Vascular endothelial growth factor‐A determines detectability of experimental melanoma brain metastasis in GD‐DTPA‐enhanced MRI.
Authors: Leenders William , Küsters Benno , Pikkemaat Jeroen , Wesseling Pieter , Ruiter Dirk , Heerschap Arend , Barentsz Jelle , de Waal Robert MW 
Published: April 2003

AbstractWe have previously shown that the dense vascular network in mouse brain allows for growth of human melanoma xenografts (Mel57) by co‐option of preexisting vessels. Overexpression of recombinant vascular endothelial growth factor‐A (VEGF‐A) by such xenografts induced functional and morphologic alterations of preexisting vessels. We now describe the effects of VEGF‐A expression on visualization of these brain tumors in mice by magnetic resonance imaging (MRI), using gadolinium diethylenetriaminepenta‐acetic acid (Gd‐DTPA) and ultra small paramagnetic iron oxide particles (USPIO) as contrast agents. Brain lesions derived from (mock‐transfected) Mel57 cells were undetectable in MRI after Gd‐DTPA injection. However, the majority of such lesions became visible after injection of USPIO, due to the lower vascular density in the lesions as compared to the surrounding parenchyma. In contrast, VEGF‐A‐expressing lesions were visualized using Gd‐DTPA‐enhanced MRI by a rapid circumferential enhancement, due to leaky peritumoral vasculature. USPIO‐enhanced MRI of these tumors corroborated the immunohistochemic finding that peritumorally located, highly irregular and dilated vessels were present, while intratumoral vessel density was low. Our study shows that VEGF‐A is a key factor in imaging of brain neoplasms. Our data also demonstrate that, at least in brain, blood‐pool agent‐enhanced MRI may be a valuable diagnostic tool to detect malignancies that are not visible on Gd‐DTPA‐enhanced MRI. Furthermore, the involvement of VEGF‐A in MRI visibility suggests that care must be taken with MRI‐based evaluation of antiangiogenic therapy, as anti‐VEGF treatment might revert a tumor to a co‐opting phenotype, resulting in loss of contrast enhancement in MRI. © 2003 Wiley‐Liss, Inc.
Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels
Authors: Krasnici Senat , Werner Alexander , Eichhorn Martin E. , Schmitt‐Sody Marcus , Pahernik Sascha A. , Sauer Birgitta , Schulze Brita , Teifel Michael , Michaelis Uwe , Naujoks Kurt , Dellian Marc 
Published: April 2003

AbstractRecently, cationic liposomes have been shown to preferentially target the angiogenic endothelium of tumors. It was the aim of our study to investigate the influence of liposomal surface charge on the uptake and kinetics of liposomes into solid tumors and tumor vasculature. Experiments were performed in the amelanotic hamster melanoma A‐Mel‐3 growing in the dorsal skinfold chamber preparation of male Syrian golden hamsters. Fluorescently labeled liposomes with different surface charge were prepared. Accumulation of i.v. injected liposomes was assessed by quantitative intravital fluorescence microscopy of tumor and surrounding host tissue. The histological distribution of liposomes was analyzed by double‐fluorescence microscopy 20 min after application of fluorescently labeled lectin as a vascular marker. After i.v. application of anionic and neutral liposomes, we observed an almost homogeneous distribution of liposome‐induced fluorescence throughout the chamber preparation without specific targeting to tumor tissue. In contrast, cationic liposomes exhibited a significantly enhanced accumulation in tumor tissue and tumor vasculature up to 3‐fold compared to surrounding tissue (p<0.05). The histological distribution of neutral and anionic liposomes revealed extravasation 20 min after i.v. injection, while cationic liposomes displayed a highly selective accumulation on the vascular endothelium. In conclusion, cationic liposomes exhibited a preferential uptake in angiogenic tumor vessels and therefore may provide an efficient tool for the selective delivery of diagnostic or therapeutic agents to angiogenic blood vessels of solid tumors. On the other hand, anionic and neutral liposomes may be used as carriers of drugs to the extravascular compartment of tumors due to their extravasation. © 2003 Wiley‐Liss, Inc.
Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability
Authors: Catto James W. F. , Xinarianos George , Burton Julian L. , Meuth Mark , Hamdy Freddie C. 
Published: April 2003

AbstractDefects in the DNA mismatch repair proteins result in microsatellite instability and malignancy in hereditary non‐polyposis colorectal carcinoma (HNPCC). However, the role of mismatch repair (MMR) proteins and microsatellite instability (MSI) in transitional cell carcinoma of the bladder is less clear. In our study, the expression of 2 MMR proteins and the frequency of MSI in Transitional cell carcinoma of the bladder (TCC) were investigated. One hundred eleven patients with TCC of the bladder were studied, with complete clinicopathological data (median follow up of 5 years, range 5–16 years). Immunohistochemistry was used to detect the expression levels of hMLH1 and hMSH2. Microsatellite analysis for 14 loci (10 loci from the Bethesda consensus panel and the repeats in the TGFβR2, BAX, hMSH3 and hMSH6 genes) was performed on 84 tumors. Reduced expression of either MMR protein was seen in 26 of 111 tumors (23%). Reduced expression was seen more commonly in muscle invasive (p<0.03) and high grade TCC (p<0.03) than in superficial, low grade tumors. By 5 years, reduced expression of either MMR protein was associated with fewer recurrences of superficial tumors (p=0.015) and fewer relapses in all tumors (p=0.03), compared to tumors with normal expression. Nine tumors had reduced expression of both MMR proteins, analysis which suggests a synergistic reduction in expression (p=0.001). MMR expression was related to patient age, younger patients being more likely to have reduced MMR expression than older patients (p<0.01). MSI was seen at multiple loci in 1 tumor (1%) and at a single locus in 6 tumors (7%). MSI was not associated with MMR expression. Our findings indicate that reduced expression of the MMR proteins may have an important contribution in the development of a subset of TCCs and suggest a potential role for MMR expression as prognostic indicators. © 2003 Wiley‐Liss, Inc.